CJC-1295 / Ipamorelin (no DAC)
CJC-1295 (no DAC) / Ipamorelin blend (GHRH-analog + ghrelin/GHS-R agonist secretagogue pair) · ≥98% (HPLC)
RUO reference blend pairing CJC-1295 without DAC (Mod GRF 1-29), a GHRH(1-29) analog, with Ipamorelin, a selective GHS-R peptide agonist, for in-vitro secretagogue-pathway studies.
- Why researchers study it
- Studied in vitro as a paired reference material for investigating two complementary nodes of the somatotrope signaling axis — the GHRH receptor and the growth-hormone-secretagogue (ghrelin) receptor — within secretagogue-pathway and receptor-pharmacology research.
- Mechanism themes in research
- GHRH-receptor (GHRH-R) agonism — CJC-1295 without DAC as a tetrasubstituted GHRH(1-29) analogGrowth-hormone-secretagogue receptor (GHS-R1a / ghrelin receptor) agonism — Ipamorelin componentComplementary dual-pathway secretagogue signaling discussed in the literatureEnzymatic-stability modifications (D-Ala2 and additional substitutions; Aib / D-2-Nal non-natural residues) as structure-activity features
- What the evidence does not establish
- Published references are in-vitro or pre-clinical and describe research context only. They do not establish safety, efficacy, or any outcome in humans or animals, and Helix makes no such claims.
- Quality markers
- ≥98% (HPLC)MS identityLot COACold-chain
This catalog item is a two-component research blend (catalog strength 20 mg) supplied as a lyophilized powder for Research-Use-Only applications. It pairs CJC-1295 without DAC (Mod GRF 1-29), a tetrasubstituted synthetic analog of growth-hormone-releasing hormone GHRH(1-29), with Ipamorelin, a pentapeptide selective agonist of the growth-hormone-secretagogue (ghrelin) receptor. Because it is a blend, no single CAS, molecular formula, or molecular weight applies; each component is characterized separately by sequence and analytical identity. The material is intended as a characterized reference standard for in-vitro and laboratory investigation only.
Component identity
CJC-1295 without DAC (Mod GRF 1-29) is a 29-residue GHRH(1-29) analog with substitutions at positions 2, 8, 15 and 27 (including D-Ala at position 2) reported in the literature to confer resistance to enzymatic cleavage; molecular formula C152H252N44O42 (~3367.9 g/mol). Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C38H49N9O5; ~711.85 g/mol; CAS 170851-70-4; PubChem CID 9831659), incorporating the non-natural residues aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal).
Mechanism themes in the literature
The two components are described in published work as acting on distinct receptors: the CJC-1295 (no DAC) component is characterized as a GHRH-receptor (GHRH-R) agonist, while the Ipamorelin component is characterized as a selective agonist at the growth-hormone-secretagogue receptor (GHS-R1a / ghrelin receptor). The pairing is of interest as a model for studying two complementary signaling nodes of the somatotrope axis in vitro.
| Full name | CJC-1295 (no DAC) / Ipamorelin blend (GHRH-analog + ghrelin/GHS-R agonist secretagogue pair) |
| Research theme | GH secretagogue |
| CAS number | |
| Molecular formula | |
| Molecular weight | |
| Purity | ≥98% (HPLC) |
| Physical form | Lyophilized powder |
| Storage | −20 °C, desiccated, protected from light |
Sequence
Reported research areas
- Receptor pharmacology and GPCR signaling assays (GHRH-R, GHS-R1a)
- Structure-activity relationship studies of peptide secretagogue analogs
- Analytical method development and peptide characterization (HPLC / MS identity)
- In-vitro somatotrope-axis and secretagogue-pathway model systems
Credible sources
- PubChem — Ipamorelin (CID 9831659)
- PubChem search — CJC-1295 (no DAC) / Mod GRF 1-29
- PubMed — Ipamorelin and growth-hormone secretagogue receptor literature
COA with every lot
Each CJC-1295 / Ipamorelin (no DAC) lot is characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, then documented in a per-lot Certificate of Analysis. Unique lot numbers tie the vial back to its synthesis batch and analytical data.
- RP-HPLC purity result (≥98% (HPLC))
- Mass-spectrometry identity confirmation
- Appearance, molecular weight, and storage
- Lot number and testing status
Specimen Certificate of Analysis
| Product | CJC-1295 / Ipamorelin (no DAC) (reference) |
| Lot | HXR-2406-105 |
| Purity (RP-HPLC) | 98%+ |
| Identity (MS) | Confirmed · |
| Appearance | Lyophilized powder |
| Storage | −20 °C, desiccated |
Representative document. Each lot has its own COA — these are quality documents, not medical claims.